<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665860</url>
  </required_header>
  <id_info>
    <org_study_id>TEXW-2001-04550</org_study_id>
    <secondary_id>2001-52102-11255</secondary_id>
    <nct_id>NCT00665860</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Soy Phytoestrogens to Prevent Bone Loss</brief_title>
  <acronym>OPUS</acronym>
  <official_title>Safety, Efficacy, and Optimal Dosage of Soy Isoflavones to Prevent Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiser Foundation Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether soy isoflavone supplementation is safe and
      effective to prevent bone loss in postmenopausal women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over-the-counter soy isoflavone supplement usage is becoming common among postmenopausal
      women. However, there is no documented scientific evidence of its long-term safety and
      efficacy in preventing osteoporosis. Our primary goal is to determine the safety, efficacy,
      and optimal dosage of isoflavone supplementation to reduce bone loss in postmenopausal women.
      The multi-state, multi-institutional design ensures that the study results are representative
      of postmenopausal women in the U.S. population. Confirming the skeletal benefits of soy
      isoflavones could translate into reduced healthcare costs related to osteoporosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>One year and two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood biochemical bone markers (osteocalcin, bone-specific alkaline phosphatase, cross-linked N-telopeptides of type 1 collagen)</measure>
    <time_frame>One year and two years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">403</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three pills per day for two years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy isoflavones</intervention_name>
    <description>Three pills that delivered 80 mg of aglycone isoflavones per day for two years</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Soy germ isoflavones</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy isoflavones</intervention_name>
    <description>Three pills that delivered 120 mg aglycone isoflavones per day for two years</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Soy germ isoflavones</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to swallow the pills

          -  No menses for 12 months

          -  Blood follicle stimulating hormone great than 30 IU/mL

          -  Lumbar spine bone mineral density t-score equal to or greater than -1.5

        Exclusion Criteria:

          -  Strict vegetarians

          -  Current or recent smokers (within last five years)

          -  Abnormal screening mammogram, Pap smear and blood chemistries

          -  Clinical diagnosis of osteoporosis, spine and/or hip fracture, cancer, liver, kidney,
             gallbladder and heart disease

          -  Clinical diagnosis of psychiatric disorder

          -  Any allergic reactions to soy products

          -  Current treatment with bisphosphonates, calcitonin, fluoride, corticosteroids,
             tamoxifen, raloxifene, HRT, premarin, farestron and letrozole

          -  Current usage of black cohosh, blue cohosh, dong quai, Caltrate 600+Soy, Estroven,
             ginseng, Healthy Women, Natural Estrogen, Opti-Soy, PhytoFem, Probalance, Promensil,
             Remifemin, Rimostil and Trinovin
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William W. Wong, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Georgia</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ellis KJ, Shypailo RS, Steinberg FM, Lewis RD, Young RL, Wong WW. Reproducibility of fan-beam DXA measurements in adults and phantoms. J Clin Densitom. 2004 Winter;7(4):413-8.</citation>
    <PMID>15618602</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>April 22, 2008</last_update_submitted>
  <last_update_submitted_qc>April 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>William W. Wong/Project Director</name_title>
    <organization>Baylor College of Medicine</organization>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Soy isoflavones</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Effective dosage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

